Psyence Biomedical Ltd. (NASDAQ:PBM – Get Free Report) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 11,000 shares, a decline of 98.4% from the October 31st total of 671,900 shares. Based on an average daily trading volume, of 104,900 shares, the short-interest ratio is currently 0.1 days. Currently, 1.8% of the shares of the stock are short sold.
Psyence Biomedical Stock Performance
NASDAQ PBM traded up $0.17 during trading on Wednesday, hitting $3.51. 142,109 shares of the stock traded hands, compared to its average volume of 57,366. Psyence Biomedical has a 12-month low of $3.01 and a 12-month high of $323.25. The firm has a 50-day simple moving average of $0.15 and a 200-day simple moving average of $0.38.
Institutional Investors Weigh In On Psyence Biomedical
An institutional investor recently bought a new position in Psyence Biomedical stock. Virtu Financial LLC bought a new stake in shares of Psyence Biomedical Ltd. (NASDAQ:PBM – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,419 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned approximately 0.30% of Psyence Biomedical at the end of the most recent quarter. Hedge funds and other institutional investors own 77.44% of the company’s stock.
About Psyence Biomedical
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
See Also
- Five stocks we like better than Psyence Biomedical
- What is a Stock Market Index and How Do You Use Them?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- The Basics of Support and Resistance
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Options Trading – Understanding Strike Price
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Psyence Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psyence Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
